Azenta Life Sciences Partners with Frenova, a Division of Fresenius Medical Care, and Nephronomics to Advance Genomic Research in Nephrology
Azenta (Nasdaq: AZTA) has announced a strategic collaboration with Frenova and Nephronomics to advance genomic research in nephrology through the MyReason® genomics research program. The initiative has already registered over 35,000 participants and aims to reach 50,000 participants within two years.
Azenta will provide genomic sequencing through GENEWIZ and manage sample storage in its global biorepository network. Nephronomics, which holds exclusive commercial rights to the MyReason dataset, will utilize AI/machine learning models to analyze the comprehensive cardio-kidney-metabolic (CKM) disease data to identify novel disease subtypes, protective genetic variants, and therapeutic targets.
Azenta (Nasdaq: AZTA) ha annunciato una collaborazione strategica con Frenova e Nephronomics per promuovere la ricerca genomica in nefrologia attraverso il programma di ricerca genomica MyReason®. L'iniziativa ha già registrato oltre 35.000 partecipanti e punta a raggiungere 50.000 partecipanti entro due anni.
Azenta fornirà il sequenziamento genomico tramite GENEWIZ e gestirà la conservazione dei campioni nella sua rete globale di biorepository. Nephronomics, che detiene i diritti commerciali esclusivi sul dataset MyReason, utilizzerà modelli di intelligenza artificiale e apprendimento automatico per analizzare i dati completi sulle malattie cardio-renali-metaboliche (CKM) al fine di identificare nuovi sottotipi di malattia, varianti genetiche protettive e potenziali target terapeutici.
Azenta (Nasdaq: AZTA) ha anunciado una colaboración estratégica con Frenova y Nephronomics para avanzar en la investigación genómica en nefrología a través del programa de investigación genómica MyReason®. La iniciativa ya ha registrado a más de 35,000 participantes y tiene como objetivo alcanzar 50,000 participantes en dos años.
Azenta proporcionará secuenciación genómica a través de GENEWIZ y gestionará el almacenamiento de muestras en su red global de biorepositorios. Nephronomics, que posee los derechos comerciales exclusivos del conjunto de datos MyReason, utilizará modelos de inteligencia artificial y aprendizaje automático para analizar los datos completos de enfermedades cardio-renales-metabólicas (CKM) con el fin de identificar nuevos subtipos de enfermedad, variantes genéticas protectoras y objetivos terapéuticos.
Azenta (나스닥: AZTA)는 Frenova 및 Nephronomics와 전략적 협력을 발표하여 MyReason® 유전체 연구 프로그램을 통해 신장학 분야의 유전체 연구를 진전시키고자 합니다. 이 이니셔티브는 이미 35,000명 이상의 참가자를 등록했으며, 2년 내에 50,000명 참가자를 목표로 하고 있습니다.
Azenta는 GENEWIZ를 통해 유전체 시퀀싱을 제공하고 글로벌 바이오리포지토리 네트워크에서 샘플 저장을 관리할 예정입니다. MyReason 데이터셋에 대한 독점 상업적 권리를 보유한 Nephronomics는 AI 및 머신러닝 모델을 활용하여 심장-신장-대사 질환(CKM) 데이터를 분석, 새로운 질병 아형, 보호 유전 변이 및 치료 표적을 식별할 것입니다.
Azenta (Nasdaq : AZTA) a annoncé une collaboration stratégique avec Frenova et Nephronomics pour faire progresser la recherche génomique en néphrologie via le programme de recherche génomique MyReason®. L’initiative a déjà enregistré plus de 35 000 participants et vise à atteindre 50 000 participants d’ici deux ans.
Azenta fournira le séquençage génomique via GENEWIZ et gérera le stockage des échantillons dans son réseau mondial de biobanques. Nephronomics, qui détient les droits commerciaux exclusifs sur la base de données MyReason, utilisera des modèles d’intelligence artificielle et d’apprentissage automatique pour analyser les données complètes sur les maladies cardio-rénales-métaboliques (CKM) afin d’identifier de nouveaux sous-types de maladies, des variants génétiques protecteurs et des cibles thérapeutiques.
Azenta (Nasdaq: AZTA) hat eine strategische Zusammenarbeit mit Frenova und Nephronomics angekündigt, um die genomische Forschung in der Nephrologie durch das MyReason®-Genomforschungsprogramm voranzutreiben. Die Initiative hat bereits über 35.000 Teilnehmer registriert und strebt an, innerhalb von zwei Jahren 50.000 Teilnehmer zu erreichen.
Azenta wird genomisches Sequenzieren über GENEWIZ bereitstellen und die Probenlagerung in seinem globalen Biorepositorium-Netzwerk verwalten. Nephronomics, das die exklusiven kommerziellen Rechte am MyReason-Datensatz besitzt, wird KI- und Machine-Learning-Modelle nutzen, um die umfassenden Daten zu kardio-renalen-metabolischen (CKM) Erkrankungen zu analysieren, um neuartige Krankheitsuntertypen, schützende genetische Varianten und therapeutische Ziele zu identifizieren.
- Strategic partnership with Frenova and Nephronomics expands Azenta's presence in the growing nephrology research market
- Access to a large-scale genomics program with over 35,000 participants and growing
- Leverages Azenta's core capabilities in genomic sequencing and sample management
- None.
Insights
Azenta's strategic partnership with Frenova and Nephronomics provides entry into the growing nephrology precision medicine market, leveraging its core services.
Azenta has secured a strategic position in the emerging nephrology precision medicine market through its new partnership with Frenova and Nephronomics. The company will provide two core services: genomic sequencing through its GENEWIZ division and biospecimen storage in its global repository network.
This collaboration centers around the MyReason research program, which has already collected biospecimens from 35,000 participants with a target of 50,000 within two years. The scale of this database is significant in the nephrology field, where large genetic datasets have historically been limited compared to oncology and other therapeutic areas.
For Azenta, this represents a compelling commercial opportunity that aligns perfectly with its business model of providing end-to-end multiomics and sample management solutions. The company stands to benefit from both immediate revenue from sequencing services and longer-term recurring revenue from sample storage.
The nephrology market represents a strategic growth avenue, as cardio-kidney-metabolic diseases affect hundreds of millions globally. By partnering with Frenova (a division of Fresenius Medical Care, a global leader in dialysis services) and Nephronomics (which holds exclusive commercial rights to the dataset), Azenta gains access to established distribution channels and specialized expertise in this therapeutic area.
What distinguishes this partnership is the comprehensive nature of the Nephronomics Atlas, which combines genomic data with detailed clinical information. This allows for identification of novel disease subtypes and potential therapeutic targets through AI/machine learning analysis - potentially leading to recurring business opportunities as discoveries progress toward clinical development.
This partnership positions Azenta as a key infrastructure provider in nephrology precision medicine, leveraging one of the largest kidney disease genomic databases.
The collaboration between Azenta, Frenova, and Nephronomics represents a significant advancement in applying genomic medicine to nephrology, an area that has lagged behind fields like oncology in precision medicine approaches. The MyReason program, with its 35,000 participants and growing database, addresses a critical gap in kidney disease research: the lack of large-scale genomic datasets linked to detailed clinical information.
What makes this partnership particularly valuable is the combination of Frenova's access to patient populations through Fresenius Medical Care (one of the world's largest providers of dialysis services), Nephronomics' AI/machine learning capabilities, and Azenta's technical infrastructure for both sequencing and biospecimen management.
The whole genome sequencing approach being employed is noteworthy compared to more limited genotyping methods. By capturing the complete genetic code of participants, researchers can identify rare variants and structural changes that may be missed by targeted approaches. This comprehensive genetic information, when combined with the extensive clinical data available through Fresenius' network, creates exceptional opportunities for discovering novel disease mechanisms.
For nephrology research, this initiative addresses a significant challenge: kidney diseases are often heterogeneous conditions with multiple underlying mechanisms that appear clinically similar. The ability to stratify patients based on genetic profiles could lead to more targeted therapeutic approaches and better clinical trial design.
Azenta's role in this ecosystem positions it as an essential infrastructure provider, supporting the technical requirements for both data generation and sample preservation. As precision medicine in nephrology advances, Azenta's established position in this collaboration could lead to expanded opportunities as additional cohorts, biomarkers, and analytical methods are incorporated into kidney disease research programs.
The MyReason research program is an innovative initiative designed to uncover insights into the genetic mechanisms underlying kidney disease. To date, more than 35,000 participants have been registered in the program and provided biospecimens, with a goal of reaching 50,000 participants over the next two years.
Nephronomics holds exclusive commercial rights to the MyReason dataset, which anchors the Nephronomics Atlas, an unparalleled resource of deep clinical and genomic cardio-kidney-metabolic (CKM) disease data. Nephronomics aims to develop targeted therapies and redefine CKM disease care through precision medicine insights. By leveraging proprietary artificial intelligence (AI)/machine learning (ML) models trained on this comprehensive dataset, Nephronomics identifies novel disease subtypes, protective genetic variants, and therapeutic targets.
Azenta will support the collaboration by delivering genomic sequencing through GENEWIZ and managing long-term sample storage within its global biorepository network. With decades of experience in multiomics analysis and sample management solutions, Azenta is uniquely positioned to provide end-to-end solutions for complex research programs.
"We are thrilled to partner with Frenova and Nephronomics and contribute to the MyReason research program," said Ginger Zhou, President, GENEWIZ. "This collaboration represents a significant step forward in our shared mission to advance precision medicine and improve outcomes for patients."
"This large-scale whole genome sequencing initiative marks a pivotal milestone in our journey to build the most comprehensive genotype-phenotype database for patients with CKM diseases," said Jan Walter, President of Frenova. "We are equally excited to collaborate with Nephronomics on the interrogation of the Nephronomics Atlas, which promises to unlock unprecedented insights that could transform patient care."
"Frenova's MyReason initiative and unparalleled expertise in nephrology, combined with Azenta's state-of-the-art genomic sequencing and sample management solutions, represent essential cornerstones of the Nephronomics Atlas," said James Sietstra, Founder of Nephronomics. "This powerful collaboration will enable us to unlock new insights that not only advance scientific understanding but also pave the way for revolutionary therapies and diagnostics in the cardio-kidney-metabolic field."
About Nephronomics
Nephronomics is a joint venture with Fresenius Medical Care assembling the world's largest vertically integrated cardio-kidney-metabolic (CKM) disease database and deep learning model with >35,000 patients consented. Our CKM Disease Atlas contains matching whole genome and longitudinal clinical data of patients with advanced CKD and ESKD including comprehensive laboratory data, diagnosis histories, treatments, and raw radiology films. For more information, please visit www.nephronomics.com.
About Frenova
Frenova is a Fresenius Medical Care company that operates as a global Site Management Organization (SMO) dedicated to the management and execution of third-party clinical trials focusing on Cardio-Kidney-Metabolic (CKM) related therapeutic areas. Leveraging our relationship with Fresenius Medical Care's global dialysis clinics and partner nephrology practices, Frenova provides access to a global site network, streamlined procedures, and technology-enabled subject screening and enrollment.Frenova also offers data analytics and licensing services, with access to one of the nephrology industry's largest longitudinal patient databases. For more information visit the company's website at www.frenova.com.
About Azenta Life Sciences
Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions worldwide, enabling life science organizations around the world to bring impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. Our global team delivers and supports these products and services through our industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, and Barkey.
Azenta is headquartered in
INVESTOR CONTACTS:
Yvonne Perron
Vice President, Financial Planning & Analysis, and Investor Relations
ir@azenta.com
Sherry Dinsmore
sherry.dinsmore@azenta.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/azenta-life-sciences-partners-with-frenova-a-division-of-fresenius-medical-care-and-nephronomics-to-advance-genomic-research-in-nephrology-302518887.html
SOURCE Azenta
FAQ
What is the purpose of Azenta's collaboration with Frenova and Nephronomics?
How many participants are currently enrolled in the MyReason genomics research program?
What role will Azenta play in the MyReason research program?
What is the Nephronomics Atlas and how will it be used?
How will this partnership benefit AZTA's business operations?
